These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1561 related articles for article (PubMed ID: 29769722)

  • 1. Bystander CD8
    Simoni Y; Becht E; Fehlings M; Loh CY; Koo SL; Teng KWW; Yeong JPS; Nahar R; Zhang T; Kared H; Duan K; Ang N; Poidinger M; Lee YY; Larbi A; Khng AJ; Tan E; Fu C; Mathew R; Teo M; Lim WT; Toh CK; Ong BH; Koh T; Hillmer AM; Takano A; Lim TKH; Tan EH; Zhai W; Tan DSW; Tan IB; Newell EW
    Nature; 2018 May; 557(7706):575-579. PubMed ID: 29769722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bystander CD4
    Li S; Zhuang S; Heit A; Koo SL; Tan AC; Chow IT; Kwok WW; Tan IB; Tan DSW; Simoni Y; Newell EW
    Oncoimmunology; 2022; 11(1):2012961. PubMed ID: 36524209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39
    Liu T; Tan J; Wu M; Fan W; Wei J; Zhu B; Guo J; Wang S; Zhou P; Zhang H; Shi L; Li J
    Gut; 2021 Oct; 70(10):1965-1977. PubMed ID: 33262196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells.
    Martinez-Usatorre A; Carmona SJ; Godfroid C; Yacoub Maroun C; Labiano S; Romero P
    Front Immunol; 2020; 11():340. PubMed ID: 32174925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant Expression of CD39, CD69, and CD103 Identifies Antitumor CD8
    Lama GIG; Noél G; Márquez FCL; Galarza FFG; Hinojosa AIP; Rivera LEN; Willard-Gallo K; Astorga JRA
    Curr Pharm Biotechnol; 2024; 25(13):1747-1757. PubMed ID: 37680154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically driven CD39 expression shapes human tumor-infiltrating CD8
    Gallerano D; Ciminati S; Grimaldi A; Piconese S; Cammarata I; Focaccetti C; Pacella I; Accapezzato D; Lancellotti F; Sacco L; Caronna R; Melaiu O; Fruci D; D'Oria V; Manzi E; Sagnotta A; Parrino C; Coletta D; Peruzzi G; Terenzi V; Battisti A; Cassoni A; Fadda MT; Brozzetti S; Fazzi K; Grazi GL; Valentini V; Chirletti P; Polimeni A; Barnaba V; Timperi E
    Int J Cancer; 2020 Nov; 147(9):2597-2610. PubMed ID: 32483858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
    Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
    J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
    Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
    Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
    Caushi JX; Zhang J; Ji Z; Vaghasia A; Zhang B; Hsiue EH; Mog BJ; Hou W; Justesen S; Blosser R; Tam A; Anagnostou V; Cottrell TR; Guo H; Chan HY; Singh D; Thapa S; Dykema AG; Burman P; Choudhury B; Aparicio L; Cheung LS; Lanis M; Belcaid Z; El Asmar M; Illei PB; Wang R; Meyers J; Schuebel K; Gupta A; Skaist A; Wheelan S; Naidoo J; Marrone KA; Brock M; Ha J; Bush EL; Park BJ; Bott M; Jones DR; Reuss JE; Velculescu VE; Chaft JE; Kinzler KW; Zhou S; Vogelstein B; Taube JM; Hellmann MD; Brahmer JR; Merghoub T; Forde PM; Yegnasubramanian S; Ji H; Pardoll DM; Smith KN
    Nature; 2021 Aug; 596(7870):126-132. PubMed ID: 34290408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
    Duhen T; Duhen R; Montler R; Moses J; Moudgil T; de Miranda NF; Goodall CP; Blair TC; Fox BA; McDermott JE; Chang SC; Grunkemeier G; Leidner R; Bell RB; Weinberg AD
    Nat Commun; 2018 Jul; 9(1):2724. PubMed ID: 30006565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High proportion of PD-1 and CD39 positive CD8+ tissue resident T lymphocytes correlates with better clinical outcome in resected human oesophageal adenocarcinoma.
    Hill SL; Sugiyarto G; Harrington J; James E; Underwood TJ; Elliott T
    Cancer Immunol Immunother; 2024 Sep; 73(11):213. PubMed ID: 39235606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional HPV-specific PD-1
    Eberhardt CS; Kissick HT; Patel MR; Cardenas MA; Prokhnevska N; Obeng RC; Nasti TH; Griffith CC; Im SJ; Wang X; Shin DM; Carrington M; Chen ZG; Sidney J; Sette A; Saba NF; Wieland A; Ahmed R
    Nature; 2021 Sep; 597(7875):279-284. PubMed ID: 34471285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
    Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8
    Fehlings M; Simoni Y; Penny HL; Becht E; Loh CY; Gubin MM; Ward JP; Wong SC; Schreiber RD; Newell EW
    Nat Commun; 2017 Sep; 8(1):562. PubMed ID: 28916749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases.
    Yoong KF; Adams DH
    Br J Cancer; 1998 Apr; 77(7):1072-81. PubMed ID: 9569042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content.
    Ye SW; Wang Y; Valmori D; Ayyoub M; Han Y; Xu XL; Zhao AL; Qu L; Gnjatic S; Ritter G; Old LJ; Gu J
    J Clin Immunol; 2006 Sep; 26(5):447-56. PubMed ID: 16967323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer.
    Sukegawa K; Shitaoka K; Hamana H; Kobayashi E; Miyahara Y; Fujii K; Tsuda K; Saeki S; Nagata T; Ozawa T; Saito S; Fujii T; Muraguchi A; Shiku H; Kishi H
    Eur J Immunol; 2020 Oct; 50(10):1580-1590. PubMed ID: 32441316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.